India's CAR-T Moment: ImmunoACT, Immuneel and the Cost Revolution in Cell Therapy

When ImmunoACT shipped the first commercial doses of NexCAR19 in late 2023, it priced a therapy that costs roughly half a million dollars in the United States at between $30,000 and $50,000. Two and a half years later, the cost gap has hardened into a genuine moat. In June 2026, Immuneel Therapeutics, the Bengaluru cell-therapy company co-founded by Biocon's Kiran Mazumdar-Shaw, closed a Series B north of ₹100 crore to scale its own CD19 product, while ImmunoACT booked its first international licensing deal. India now has two approved, indigenous CAR-T therapies and a credible export thesis. The constraint on the market is no longer science or manufacturing. It is who pays.

What CAR-T actually is, and why India's version is cheaper

Chimeric antigen receptor T-cell therapy is a one-time, autologous treatment. A patient's own T-cells are extracted by leukapheresis, genetically reprogrammed to express a synthetic receptor that targets a tumour antigen (CD19 in B-cell leukaemias and lymphomas), expanded in culture, and re-infused. The reprogramming is typically done with a lentiviral vector that integrates the CAR construct into the T-cell genome. Once engrafted, the cells persist and proliferate in vivo, which is why a single dose can drive durable remissions in patients who have exhausted chemotherapy.

The science is shared with Novartis's Kymriah and Gilead's Yescarta. The cost structure is not. ImmunoACT, a spinoff from IIT Bombay led by CEO Rahul Purwar, built the entire stack domestically: the vector, the manufacturing process, and the analytics. NexCAR19, generically talicabtagene autoleucel, received CDSCO approval in October 2023 as India's first indigenous CD19 CAR-T. The company runs a 200-litre GMP facility that it says supports up to 1,000 patients per year, and has treated 500 to 600-plus patients across more than 80 hospitals. Localised vector production, lower clinical and labour costs, and a vein-to-vein process designed for Indian hospital logistics compress the price by roughly 10x against US and European list prices. That is the headline number investors should anchor on: not a discount, an order of magnitude.

Immuneel's Qartemi (varnimcabtagene autoleucel) is the second entrant, approved by CDSCO in January 2025. It is an anti-CD19 construct using a 4-1BB costimulatory domain, the same signalling architecture associated with longer T-cell persistence in Kymriah. The company reports an 83.3% overall response rate at 90 days in its Phase II IMAGINE trial. Two approved products with different costimulatory designs give India a small but real competitive market rather than a single-vendor experiment.

The money: funding rounds and the financing bottleneck

Immuneel's ₹100 crore-plus Series B in June 2026 drew Singularity AMC, Rainmatter (Zerodha's investment arm), Eight Roads and F-Prime. The investor mix matters. Rainmatter signals domestic conviction that cell therapy can be a venture-scale business in India; Eight Roads and F-Prime bring deep-tech biotech credentials. On the ImmunoACT side, Laurus Labs is the largest backer with more than $18 million committed, anchoring a listed-pharma balance sheet behind a clinical-stage platform.

Yet the binding constraint sits downstream of the cap table. By industry estimates, only about 1% of eligible Indian patients are currently treated. The reason is not supply. CAR-T is not yet covered under Ayushman Bharat PM-JAY, the national health insurance scheme, so the cost falls on households. Even at one-tenth the US price, ₹25 to ₹40 lakh out of pocket is out of reach for the overwhelming majority of patients who need it. The single most important catalyst for this market is a payer decision, not a clinical readout.

The ecosystem is improvising workarounds. GST on gene therapy and CAR-T was removed effective 16 January 2025, shaving indirect tax off the bill. In December 2025, Mango Sciences introduced 0%-interest bridge financing to spread payments. These help at the margin. They do not substitute for inclusion in public insurance, which would convert a thin self-pay market into a structurally larger one. For investors, the asymmetry is clear: the manufacturing and regulatory risk has largely been retired; the reimbursement risk has not.

The export thesis

If domestic demand is gated by reimbursement, the near-term growth story may run through exports. In January 2026, Cipla licensed NexCAR19 for Africa, beginning with South Africa, Algeria and Morocco. This is the first export of an Indian CAR-T therapy, and it reframes the opportunity. India is not just a low-cost domestic supplier; it is positioned to become a manufacturing base for cell therapy across price-sensitive markets that branded Western products have never served.

The logic mirrors India's generics and vaccine playbook. A cost base an order of magnitude below incumbents, paired with a partner like Cipla that already has African regulatory and distribution reach, turns a manufacturing moat into a market-access moat. The total addressable market here is defined less by India's roughly 1.4 billion people and more by the global cohort of relapsed/refractory B-cell malignancy patients in low- and middle-income countries who are currently treated with palliative chemotherapy because licensed CAR-T is unaffordable.

Risks and what to watch

Cell therapy is operationally unforgiving, and several caveats deserve weight. Autologous manufacturing does not enjoy the per-unit economics of a small molecule; every dose is a bespoke batch, and gross margins depend on yield, facility utilisation and out-of-spec rates that are hard to verify from outside. The 1,000-patients-per-year capacity figure is a stated ceiling, not demonstrated throughput. Response-rate data such as the 83.3% ORR is early and single-trial; durability, relapse and long-term safety (cytokine release syndrome and neurotoxicity management) determine real-world value.

There is also a structural question. Allogeneic, off-the-shelf CAR-T and in-vivo approaches are advancing globally and could eventually undercut autologous cost advantages by removing the per-patient manufacturing burden. India's lead today is in autologous economics; that is the platform that must keep improving.

The base case is still constructive. Two approved indigenous products, a verified order-of-magnitude cost advantage, a listed-pharma backer in Laurus, fresh venture capital into Immuneel, and a first export deal together de-risk the thesis that India can be the world's low-cost cell-therapy manufacturer. The variable that converts that thesis into a large domestic market is policy. The day CAR-T enters PM-JAY, the addressable patient pool widens by two orders of magnitude. Until then, watch the export pipeline and the reimbursement file with equal attention.